Biotechnology Value Fund L P

disclosed that they own 5.1% of Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) in a Schedule 13G disclosure that was filed with the SEC on Friday, August 11th. The investor owns 652,676 shares of the stock valued at about $7,825,585. The reporting parties listed on the disclosure included Biotechnology Value Fund, LP, Biotechnology Value Fund II, LP, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd, BVF Partners LP, BVF Inc and Mark N Lampert. The filing is available through EDGAR at this hyperlink.

Biotechnology Value Fund L P

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(https://whalewisdom.com
652,676
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

A number of other hedge funds have also modified their holdings of SBPH. Parsons Capital Management Inc. RI raised its stake in Spring Bank Pharmaceuticals by 19.6% in the first quarter. Parsons Capital Management Inc. RI now owns 233,443 shares of the company’s stock worth $2,078,000 after buying an additional 38,278 shares during the last quarter. Private Capital Advisors Inc. raised its stake in Spring Bank Pharmaceuticals by 50.0% in the second quarter. Private Capital Advisors Inc. now owns 56,250 shares of the company’s stock worth $762,000 after buying an additional 18,750 shares during the last quarter. Morse Asset Management Inc raised its stake in Spring Bank Pharmaceuticals by 156.9% in the second quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after buying an additional 38,900 shares during the last quarter. C WorldWide Group Holding A S purchased a new stake in Spring Bank Pharmaceuticals during the second quarter worth $340,000. Finally, Sphera Funds Management LTD. purchased a new stake in Spring Bank Pharmaceuticals during the second quarter worth $2,370,000. Institutional investors own 9.82% of the company’s stock.

Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) traded up 1.18% during mid-day trading on Friday, hitting $11.99. 18,515 shares of the company were exchanged. The stock’s market cap is $152.24 million. Spring Bank Pharmaceuticals, Inc. has a 12 month low of $6.31 and a 12 month high of $16.97. The firm has a 50 day moving average price of $14.08 and a 200 day moving average price of $11.19.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.watchlistnews.com/spring-bank-pharmaceuticals-inc-nasdaqsbph-stake-maintained-by-biotechnology-value-fund-l-p/1476195.html.

SBPH has been the topic of a number of recent research reports. Chardan Capital initiated coverage on shares of Spring Bank Pharmaceuticals in a research note on Monday, May 1st. They set a “buy” rating and a $16.50 target price on the stock. JMP Securities initiated coverage on shares of Spring Bank Pharmaceuticals in a research note on Friday, May 19th. They set a “market perform” rating and a $20.00 target price on the stock. ValuEngine upgraded shares of Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th. Finally, Cantor Fitzgerald initiated coverage on shares of Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They set an “overweight” rating and a $29.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $26.25.

In related news, Director Kurt M. Eichler bought 76,923 shares of the company’s stock in a transaction that occurred on Tuesday, June 27th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $999,999.00. Following the acquisition, the director now owns 582,533 shares in the company, valued at approximately $7,572,929. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Arkowitz bought 2,500 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were bought at an average price of $12.24 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the director now owns 17,086 shares in the company, valued at approximately $209,132.64. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 81,423 shares of company stock worth $1,055,319. Company insiders own 17.60% of the company’s stock.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Want to see what other hedge funds are holding SBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH).

Institutional Ownership by Quarter for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.